Belgian university hospitals UZ Leuven and KU Leuven are investing €14 million in a new facility for the production of Advanced Therapy Medicinal Products (ATMPs). It’s expected to be operational by the end of 2025.
The new centre will place the Belgian institutions at the forefront of cell and gene therapy development, offering personalised treatments for complex conditions. The ATMP facility will focus on conditions where standard treatments often fall short, such as haematological malignancies, brain cancers, and rare genetic diseases.
With the new facility, UZ Leuven and KU Leuven are set to play a leading role in personalised medicine. By ensuring local production of ATMPs and fostering collaboration between clinicians and researchers, they are committing to providing innovative therapies to patients sooner and advancing global medical research.
“New therapeutic possibilities will become available to patients more quickly. We’re building a bridge between academic research and clinical application, offering new hope for those with rare and complex diseases,” Bart Geers, investment manager at KU Leuven Research & Development, concluded.